If, at any time, the aggregate rate of treatment-related toxicities meeting DLT criteria exceeds 33% across all par ticipants treated, the findings w ill be discussed and further enrollment will be interrupted. Depending on the nature and the grade of the toxicity, and after assessing the risk/benefit ratio, a new dose for all c ohorts may be initiated at a lower dose level. The dose and schedule of BMS-986226 in Parts D and E will be determined based on all available safety, tolerability, efficacy, PK, and PD data from Parts A, B, and C. Parts D and E will e nroll approximately 40 participants in each cohort. Safety, efficacy, PK, and PD data w ill be used to determine the precise patient population that will be enrolled in the expansion arms. •Participants will be enrolled using the Inter active Response Technology (IRT) during the screening phase. •For Parts A, scans will be collected centrally and may be reviewed by BICR at a later date or at any time during the study. For Parts B, C, D and E scans will be collected cen trally to be reviewed in real t ime by BICR. Number of Participants: The number of participants for this study will be approximately 234. Up to approximately 34 of these participants may be treated with monotherapy (Preliminary Safety Cohorts and Part A); approximately 6 evaluable participants may be treated at each dose level for Parts B1 and C1; approximately 6-12 evaluable participants may be treated at each dose level for Parts B2 and C2;up to 6 additional evaluable participants may be treated in Parts B and/or C at a recommended BMS-986226 dose regimen for Parts D and/or E to better characterize the safety, PK, and PDprofile; approximately 80 participants will be treated in combination expansion arms, Parts D and E. Study Phases and Duration: Screening: The screening phase will last for up to 28 days and take place prior to the first administration of study treatment for all parts.